Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 6/20 | 0.68 |
| ▸ | GFER | P55789 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8233143 | 0.84 | ALDH1A1 (0.58) | APOBEC3GGFERLMNATDP1CA9 | |
| SCHEMBL25271059 | 0.83 | ALDH1A1 (0.47) | APOBEC3GGFERLMNATDP1ALDH1A1 | |
| SCHEMBL8227328 | 0.83 | APOBEC3G (0.51) | APOBEC3GGFERLMNATDP1CA9 | |
| SCHEMBL8738538 | 0.83 | APOBEC3G (0.51) | APOBEC3GGFERLMNATDP1CA9 | |
| SCHEMBL3986959 | 0.83 | GAA (0.54) | APOBEC3GGFERLMNATDP1ALDH1A1 | |
| SCHEMBL4270680 | 0.81 | APOBEC3G (0.61) | APOBEC3GGFERLMNATDP1CA9 | |
| SCHEMBL8978563 | 0.81 | APOBEC3G (1.00) | APOBEC3GGFERLMNATDP1CA9 | |
| SCHEMBL9354368 | 0.80 | ALDH1A1 (0.70) | APOBEC3GGFERLMNATDP1ALDH1A1 | |
| SCHEMBL166328 | 0.80 | MAPT (0.48) | APOBEC3GGFERLMNATDP1CA9 | |
| SCHEMBL8232792 | 0.80 | APOBEC3G (0.48) | APOBEC3GGFERLMNATDP1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5436252-A | Antiischemic agents, stroke, Alzheimer's or Parkinson's diseases | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-07-25 | — | — | US | claimed |
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| EP-2027096-B1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | Bayer Pharma AG (DE) | 2012-05-23 | — | — | EP | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| WO-2007134862-A1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER HEALTHCARE AG (DE) | 2007-11-29 | — | — | WO | disclosed |
| US-5436252-A | Antiischemic agents, stroke, Alzheimer's or Parkinson's diseases | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0273310-B1 | 5-Aryl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants | MERRELL DOW PHARMA (US) | 1995-06-21 | — | — | EP | disclosed |
| US-5391561-A | Microbiocides | ROHM AND HAAS COMPANY (US) | 1995-02-21 | — | — | US | disclosed |
| EP-0273309-B1 | 5-Aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders | MERRELL DOW PHARMA (US) | 1995-01-11 | — | — | EP | disclosed |
| EP-0404498-B1 | Novel halo propargyl compounds, and uses and processes of preparation thereof | ROHM & HAAS (US) | 1994-10-19 | — | — | EP | disclosed |
| US-5292762-A | Halopropargyl compounds, compositions, uses and processes of preparation | ROHM AND HAAS COMPANY (US) | 1994-03-08 | — | — | US | disclosed |
| US-5064845-A | Heterocyclic iodopropargly compounds | ROHM AND HAAS COMPANY (US) | 1991-11-12 | — | — | US | disclosed |
| EP-0404498-A2 | Novel halo propargyl compounds, and uses and processes of preparation thereof | ROHM AND HAAS COMPANY (US) | 1990-12-27 | — | — | EP | disclosed |
| US-4946856-A | 5-phenyl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-08-07 | — | — | US | disclosed |
| EP-0273309-A2 | 5-Aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | AVPR2, AVPR1A, AVPR1B | APOBEC3G 3518/4885GFER 2439/4885LMNA 2681/4885 |
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | AVPR2, AVPR1A, AVPR1B | APOBEC3G 3518/4885GFER 2439/4885LMNA 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.